EXOme Rare Cancers in Children (EXOCARE) (EXOCARE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03472807|
Recruitment Status : Recruiting
First Posted : March 21, 2018
Last Update Posted : February 6, 2020
Other than high-dose radiation and previous chemotherapy, few strong risk factors have been identified as causes of childhood cancer. Geneticists estimate that 5 to 10% of all cancers diagnosed during the paediatric period occur in children born with a genetic mutation, increasing their lifetime risk of neoplasia. Such genetic risk is higher in children with congenital anomalies and specific genetic syndromes. Some germline genetic alterations are well known (e.g. P53 protein (P53), Neurofibromatosis type 1(NF1)), however many children with none of these mutations have clinical presentations that strongly suggest the involvement of a genetic predisposition. Comprehensive genetic testing for all such patients is an important factor for improving disease surveillance. Such opportunities are now available thanks to whole exome sequencing (WES). In oncology, an important clinical application of WES will be to routinely identify mutations associated with inherited cancer predispositions and to guide cancer risk-management decisions.
Our project is a national translational multicenter genetics study aimed at identifying genes involved in paediatric cancer predisposition by WES in a very select population of children with both developmental delay and cancer. Our project relies on the TED register (Tumeur Et Développement), an initiative by the French organisation SFCE (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent) involving 30 child cancer units in France. This database includes the information of more than 500 paediatric cancer patients with congenital abnormalities. The investigators plan to sequence the germline and tumour exome of 100 patients with developmental delay in a trio-design consisting of 300 people and 100 tumours.
The investigators believe that the ExoCaRe project will provide answers to the genetic origins of certain particular childhood cancers. The ExoCaRe project relies on a genetic study to identify genetic risk factors for rare forms of childhood cancer and aims to establish more personalised treatment. It is aimed at improving genetic counselling for families and will be fully integrated in the genetic counselling process. The information provided by our study will be used to improve the management approach to an initial cancer by clarifying the risks of other cancers in related families. The investigators hope to identify new germline genes predisposing to cancer that will be of interest in understanding tumour biology.
|Condition or disease||Intervention/treatment||Phase|
|Predisposition, Genetic Cancer Childhood Development Delay||Other: Collection of blood sample or saliva Other: Collection of a tumor sample taken before the participation of the patient in study Other: Collection of blood sample if tumor sample is not available||Not Applicable|
-Primary objective : Our aim is to identify new mutations and genes involved in paediatric cancer predisposition associating developmental delay by WES of a sub-cohort of patients included in the TED database.
-Secondary objectives :
- Describe inherited predisposition to cancer.
- Improve genetic counselling processes.
- Initiate clinical exome sequencing in childhood cancer treatment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Factorial Assignment|
|Intervention Model Description:||prospective multicenter study, not therapeutic,|
|Masking:||None (Open Label)|
|Official Title:||An Investigation of Susceptibility Genes for Rare Cancers in Children by Exome Sequencing|
|Actual Study Start Date :||November 13, 2019|
|Estimated Primary Completion Date :||November 13, 2021|
|Estimated Study Completion Date :||January 13, 2022|
Other: Collection of blood sample or saliva
Other: Collection of a tumor sample taken before the participation of the patient in study
Other: Collection of blood sample if tumor sample is not available
Parent of cancer patient
-Collection of blood sample or saliva
Other: Collection of blood sample or saliva
- Number and type of germline and somatic genetic variants of pathological significance and associated with the disease. [ Time Frame: At inclusion ]
WES and RNA sequence data will be used to identify and characterise germline and somatic genetic variants of pathological significance and associated with the disease.
Descriptive statistics, such as counts and proportions of variants of pathological significance risk will be computed within each patient and family.
- Related to secondary objectives (1) : Identification of biological pathways involved in childhood cancer predisposition. [ Time Frame: At inclusion ]The deleterious mutations that the investigators will identify in genes related to childhood cancer predisposition will help to have a comprehensive framework of biological pathways involved in childhood cancer predisposition.
- Related to secondary objectives (2) : Overall success rate. [ Time Frame: At inclusion ]Success is defined by the combined successes of quality interpretable genomic data are generated from sequencing tumor and germline tissues, and communicating genomic test results to the primary oncologist and the patient and his/her parents.
- Related to secondary objectives (3) : Number of clinical criteria justifying a WES. [ Time Frame: At inclusion ]Descriptive statistics, such as counts and proportions of success by clinical presentation of the disease, by cancer types, by features of developmental delay, and, by class of age.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03472807
|Contact: Elsa BERARDI||+33 2 41 35 61 email@example.com|
|Principal Investigator:||Isabelle PELLIER, Pr||UH Angers|